Table 1.
Characteristics of study participants.
| Patient Characteristics (n=49) |
Control (n=31) | COVID-19 (n=18) | P value |
|---|---|---|---|
| Age, y | |||
| Mean | 38.5 | 43.3 | 0.3098 a |
| Median | 36 | 36 | |
| Range | 19-71 | 19-65 | |
| Sex, No. (%) | |||
| Male | 12 (39%) | 12 (67%) | 0.0792 b |
| Female | 19 (61%) | 6 (33%) | |
| Race, No. (%) | |||
| White | 27 (87%) | 15 (83%) | >0.9999 c |
| Black or African American | 0 (0%) | 0 (0%) | |
| Asian | 2 (6%) | 2 (11%) | |
| More than one race | 0 (0%) | 1 (6%) | |
| Unknown/Not reported | 2 (6%) | 0 (0%) | |
| Ethnicity, No. (%) | |||
| Non-Hispanic | 21 (68%) | 13 (72%) | >0.9999 d |
| Hispanic | 5 (16%) | 4 (22%) | |
| Unknown/Not reported | 5 (16%) | 1 (6%) | |
| Co-morbidities, No. (%) | |||
| ADHD | 0(0%) | 1 (6%) | 0.3673 e |
| Allergy | 0 (0%) | 1 (6%) | >0.9999 e |
| Anxiety/Depression | 5 (16%) | 2 (11%) | >0.9999 e |
| Arthritis | 0 (0%) | 1 (6%) | 0.3673 e |
| Asthma | 1 (3%) | 2 (11%) | 0.5475 e |
| BPH | 0 (0%) | 1 (6%) | 0.3673 e |
| Diabetes | 2 (6%) | 0 (0%) | 0.5255 e |
| GERD | 0 (0%) | 1 (6%) | 0.3673 e |
| Gout | 1 (3%) | 1 (6%) | >0.9999 e |
| HIV | 1 (3%) | 0 (0%) | >0.9999 e |
| HLD/CAD | 1 (3%) | 2 (11%) | 0.5475 e |
| Hypertension | 2 (6%) | 1 (6%) | >0.9999 e |
| Hypothyroidism | 2 (6%) | 2 (11%) | 0.6181 e |
| Obesity | 0 (0%) | 1 (6%) | 0.3673 e |
| Osteoporosis | 0 (0%) | 3 (17%) | 0.0443 e |
| Parkinson’s disease | 1 (3%) | 0 (0%) | >0.9999 e |
| Seizure disorder | 1 (3%) | 1 (6%) | >0.9999 e |
a
Data analyzed using unpaired t-test with Welch’s correction.
b
Data analyzed using Fisher’s exact test (male vs. female).
c
Data analyzed using Fisher’s exact test (white vs. non-white).
d
Data analyzed using Fisher’s exact test (Non-Hispanic vs. Hispanic).
e
Data analyzed using Fisher’s exact test (Negative vs. Positive).
ADHD, attention deficit and hyperactivity disorder; BPH, benign prostatic hyperplasia; GERD, gastroesophageal reflux disease; HIV, human immunodeficiency virus; HLD/CAD, hyperlipidemia/coronary artery disease.